Skip to content
Clinical Trials – home

Fakultni nemocnice Motol a Homolka

Verifiedinfo

Czechia V Uvalu 84/1, Motol, 150 00 Prague, Czechia

  • 148 trials recruiting
  • Non-small cell lung cancer · Bladder transitional cell carcinoma · Breast cancer
  • Adults and children

About Specializations

Fakultni nemocnice Motol a Homolka in Prague, Czechia specialises in clinical trials of conditions such as Non-small cell lung cancer, Bladder transitional cell carcinoma, Breast cancer, Hidradenitis, and other specialisations. This site conducts important research.

Main research areas of the site

Musculoskeletal Diseases and Skin and Connective Tissue Diseases

Clinical research at Fakultni nemocnice Motol a Homolka focuses on inflammatory conditions that affect joints, skin, and connective tissues, with a strong emphasis on psoriatic arthritis. The trials are designed to assess whether new treatment options can better control disease activity and improve patient outcomes.

  • Evaluating new therapies for psoriatic arthritis
  • Comparing treatment effectiveness against placebo and established options
  • Measuring improvement in symptoms and overall disease control

This research reflects a collaborative clinical environment in Praha, where specialists in rheumatology are working to expand treatment choices for people with active inflammatory disease.

Psoriatic Arthritis Research

The site is conducting studies centered on psoriatic arthritis, a condition that links musculoskeletal inflammation with skin and connective tissue involvement. The main goal is to determine how well emerging therapies can reduce disease signs and support better long-term management.

  • Testing potential new treatment approaches for active disease
  • Assessing benefit in patients who have not responded adequately to prior therapy
  • Supporting better decisions in inflammatory arthritis care

With experienced investigators at Oddělení revmatologie dětí a dospělých, the research program brings together both adult and pediatric rheumatology expertise.

Inflammatory Joint and Tissue Disease Trials

These trials explore treatment strategies for diseases within the musculoskeletal and connective tissue fields, aiming to improve symptom control and overall response in people living with chronic inflammatory arthritis.

  • Studying whether newer therapies can improve disease activity
  • Comparing investigational treatments with reference therapies
  • Advancing care for patients with persistent inflammatory joint disease

The research activity at this health care institution in Czechia highlights a strong clinical focus on practical treatment improvement rather than basic laboratory work.

Rheumatology Clinical Research

Clinical trials at the site are concentrated in rheumatology, especially conditions where inflammation affects both joints and skin. The studies aim to clarify which therapies may offer better relief for patients with active psoriatic arthritis.

  • Investigating treatment effectiveness in active inflammatory disease
  • Exploring options for patients with inadequate response to standard care
  • Contributing to more personalized management of chronic arthritis

With a substantial investigator base, Fakultni nemocnice Motol a Homolka supports ongoing clinical evaluation of new approaches in a specialized rheumatology setting.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
V Uvalu 84/1, Motol150 00 PragueCzechia
Recruiting now
148 trials
Conditions studied
193
Partner status
Verified

More sites in PragueCzechia

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

320 clinical trials

Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:SPY002
  • Sponsor:Spyre Therapeutics Inc.
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Eli Lilly & Co.
Countries:CzechiaCzechia
  • Participants:18–64 years
  • Substances:Bevacizumab
  • Sponsor:Amgen Inc.
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:BioNTech SE
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:SPY002
  • Sponsor:Spyre Therapeutics Inc.
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:NAVENIBART
  • Sponsor:Astria Therapeutics Inc.
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:VISUGROMAB
  • Sponsor:CatalYm GmbH
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Summit Therapeutics Inc.
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST GDNF FAMILY RECEPTOR ALPHA-LIKE
  • Sponsor:Ngm Biopharmaceuticals Inc.
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Ferring Pharmaceuticals A/S
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Apg777
  • Sponsor:Apogee Therapeutics Inc.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.